Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Quidel Corporation
  6. Summary
    QDEL   US74838J1016

QUIDEL CORPORATION

(QDEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
130.29(c) 127.62(c) 124.76(c) 117.5(c) 114.88(c) Last
887 551 820 301 699 006 1 136 055 911 940 Volume
+4.99% -2.05% -2.24% -5.82% -2.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 579 M - -
Net income 2021 644 M - -
Net cash position 2021 568 M - -
P/E ratio 2021 7,64x
Yield 2021 -
Sales 2022 940 M - -
Net income 2022 231 M - -
Net cash position 2022 1 165 M - -
P/E ratio 2022 21,4x
Yield 2022 -
Capitalization 4 788 M 4 788 M -
EV / Sales 2021 2,67x
EV / Sales 2022 3,85x
Nbr of Employees 1 370
Free-Float -
More Financials
Company
Quidel Corporation is a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems. The Company is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions, and... 
More about the company
Ratings of Quidel Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about QUIDEL CORPORATION
01/11US to Require Insurers to Pay for At-Home COVID-19 Tests
MT
01/06QUIDEL : ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER 2021; QUIDEL TO PRESENT VIRTUALL..
PU
01/06Quidel Reports Preliminary Figures for Q4'21
MT
01/06Quidel Announces Preliminary Revenue for Fourth Quarter 2021
BU
01/06Quidel Corporation Provides Revenue Guidance for the Fourth Quarter 2021 and Full Year ..
CI
01/05The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand ..
AQ
01/04ORTHO CLINICAL INVESTOR ALERT BY THE : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
PR
01/04Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
BU
2021Quidel Says Its COVID Antigen Tests Detect Omicron
MT
2021Quidel's Antigen Tests Detect the Omicron Variant
BU
2021HC Wainwright Downgrades Ortho Clinical Diagnostics to Neutral From Buy Amid Deal to Be..
MT
2021EPAY, QDEL, EBMT, ABTX STOCK ALERT : Halper Sadeh LLP Investigates Mergers of EPAY, QDEL, ..
PR
2021ANALYST RECOMMENDATIONS : Foot Locker, Frontline, Quidel, StoneCo, Victoria's Secret...
2021SHAREHOLDER ALERT : WeissLaw LLP Investigates Ortho Clinical Diagnostics Holdings plc
PR
2021Scientific Games, Stitch Fix rise; Crocs, Quidel fall
AQ
More news
News in other languages on QUIDEL CORPORATION
01/11Les États-Unis vont obliger les assureurs à payer les tests COVID-19 à domicile
01/06Quidel publie des chiffres préliminaires pour le quatrième trimestre 21
01/06Quidel Corporation fournit des prévisions de chiffre d'affaires pour le quatrième trime..
2021Quidel affirme que ses tests antigènes COVID détectent l'Omicron.
2021OPINIONES DE LOS ANALISTAS DEL DÍA : Sonova, Valora, Quidel Corporation, Frontline ...
More news
Analyst Recommendations on QUIDEL CORPORATION
More recommendations
Chart QUIDEL CORPORATION
Duration : Period :
Quidel Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUIDEL CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 114,88 $
Average target price 187,00 $
Spread / Average Target 62,8%
EPS Revisions
Managers and Directors
Douglas C. Bryant President, Chief Executive Officer & Director
Randall J. Steward Chief Financial & Accounting Officer
Kenneth F. Buechler Chairman
Werner Kroll Senior Vice President-Research & Development
Karen C. Gibson SVP-Information Systems & Business Transformation
Sector and Competitors
1st jan.Capi. (M$)
QUIDEL CORPORATION-14.90%4 788
THERMO FISHER SCIENTIFIC-10.86%234 380
DANAHER CORPORATION-10.85%209 593
INTUITIVE SURGICAL, INC.-14.35%109 936
SIEMENS HEALTHINEERS AG-9.48%76 335
EDWARDS LIFESCIENCES CORPORATION-8.71%73 834